A subtype of classical Hodgkin lymphoma with scattered Reed-Sternberg and Hodgkin cells in a diffuse or vaguely nodular mixed inflammatory background without nodular sclerosing fibrosis. (WHO, 2008)
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding Hodgkin's lymphoma, mixed cellularity can be attributed to its rarity and the challenges in conducting systematic studies. As this condition affects a smaller population, comprehensive clinical data and phenotypic characterization have not been thoroughly established. This makes it difficult for patients and healthcare providers to access detailed information about the condition.
To navigate your care effectively, consider seeking a hematologist or oncologist with experience in Hodgkin lymphoma, particularly those familiar with mixed cellularity cases. While no specific patient organizations are available, resources like the National Organization for Rare Disorders (NORD) at rarediseases.org may provide valuable information and support. Engaging in clinical trials could also be an option to explore new treatments and contribute to research. Additionally, inquire about patient registries that may exist for ongoing studies.
Currently, brentuximab vedotin is the only FDA-approved treatment for Hodgkin's lymphoma, mixed cellularity. Additionally, there are two active clinical trials that may offer participation opportunities for patients. You can find more information about these trials at ClinicalTrials.gov using the search term 'Hodgkin's lymphoma, mixed cellularity'. These trials may provide access to cutting-edge therapies and contribute to the understanding of this subtype.
Actionable guidance for navigating care for Hodgkin's lymphoma, mixed cellularity
To navigate your care effectively, consider seeking a hematologist or oncologist with experience in Hodgkin lymphoma, particularly those familiar with mixed cellularity cases. While no specific patient organizations are available, resources like the National Organization for Rare Disorders (NORD) at rarediseases.org may provide valuable information and support. Engaging in clinical trials could also be an option to explore new treatments and contribute to research. Additionally, inquire about patient registries that may exist for ongoing studies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding Hodgkin's lymphoma, mixed cellularity can be attributed to its rarity and the challenges in conducting systematic studies. As this condition affects a smaller population, comprehensive clinical data and phenotypic characterization have not been thoroughly established. This makes it difficult for patients and healthcare providers to access detailed information about the condition.
To navigate your care effectively, consider seeking a hematologist or oncologist with experience in Hodgkin lymphoma, particularly those familiar with mixed cellularity cases. While no specific patient organizations are available, resources like the National Organization for Rare Disorders (NORD) at rarediseases.org may provide valuable information and support. Engaging in clinical trials could also be an option to explore new treatments and contribute to research. Additionally, inquire about patient registries that may exist for ongoing studies.
Currently, brentuximab vedotin is the only FDA-approved treatment for Hodgkin's lymphoma, mixed cellularity. Additionally, there are two active clinical trials that may offer participation opportunities for patients. You can find more information about these trials at ClinicalTrials.gov using the search term 'Hodgkin's lymphoma, mixed cellularity'. These trials may provide access to cutting-edge therapies and contribute to the understanding of this subtype.
Actionable guidance for navigating care for Hodgkin's lymphoma, mixed cellularity
To navigate your care effectively, consider seeking a hematologist or oncologist with experience in Hodgkin lymphoma, particularly those familiar with mixed cellularity cases. While no specific patient organizations are available, resources like the National Organization for Rare Disorders (NORD) at rarediseases.org may provide valuable information and support. Engaging in clinical trials could also be an option to explore new treatments and contribute to research. Additionally, inquire about patient registries that may exist for ongoing studies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding Hodgkin's lymphoma, mixed cellularity can be attributed to its rarity and the challenges in conducting systematic studies. As this condition affects a smaller population, comprehensive clinical data and phenotypic characterization have not been thoroughly established. This makes it difficult for patients and healthcare providers to access detailed information about the condition.
To navigate your care effectively, consider seeking a hematologist or oncologist with experience in Hodgkin lymphoma, particularly those familiar with mixed cellularity cases. While no specific patient organizations are available, resources like the National Organization for Rare Disorders (NORD) at rarediseases.org may provide valuable information and support. Engaging in clinical trials could also be an option to explore new treatments and contribute to research. Additionally, inquire about patient registries that may exist for ongoing studies.
Currently, brentuximab vedotin is the only FDA-approved treatment for Hodgkin's lymphoma, mixed cellularity. Additionally, there are two active clinical trials that may offer participation opportunities for patients. You can find more information about these trials at ClinicalTrials.gov using the search term 'Hodgkin's lymphoma, mixed cellularity'. These trials may provide access to cutting-edge therapies and contribute to the understanding of this subtype.
Actionable guidance for navigating care for Hodgkin's lymphoma, mixed cellularity
To navigate your care effectively, consider seeking a hematologist or oncologist with experience in Hodgkin lymphoma, particularly those familiar with mixed cellularity cases. While no specific patient organizations are available, resources like the National Organization for Rare Disorders (NORD) at rarediseases.org may provide valuable information and support. Engaging in clinical trials could also be an option to explore new treatments and contribute to research. Additionally, inquire about patient registries that may exist for ongoing studies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 1 company has orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.